ArticleFrontiers in medicine2026
Increased lymphoma risk in patients with systemic manifestations of Sjögren's disease: a population-based study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess clinical and immunological characteristics, disease activity, and lymphoma development in a well-characterized cohort of patients with Sjögren's disease, with particular emphasis on differences between glandular and systemic phenotypes. Methods: We conducted a retrospective observational study of adult patients (≥18 years) with Sjögren's disease not associated with any other systemic autoimmune rheumatic disease, defined as primary Sjögren's disease (pSjD), who were seen at a tertiary center in Madrid, Spain. Patients were classified according to the 2016 ACR/EULAR criteria or, alternatively, according to a modified version in which salivary gland ultrasonography (SGUS) was used as an alternative minor criterion when unstimulated whole salivary flow (UWS) and/or ocular staining score (OSS) were not available. For patients diagnosed before 2016, clinical data from medical records were used to apply these criteria retrospectively during the study period. SGUS findings were graded according to the Outcome Measures in Rheumatology (OMERACT) scoring system or based on expert radiologists' assessment. Systemic disease activity was assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Demographic, clinical, laboratory, histopathological, lymphoma occurrence, and treatment data were retrospectively collected. Patients were stratified into glandular (exocrine-limited) or systemic (glandular and systemic involvement) phenotypes. Results: Among 278 patients included, 148 (53%) had a glandular phenotype and 130 (47%) a systemic phenotype. The mean age at diagnosis was 54.6 (± 14.5 years); 95% were women. Sicca symptoms were highly prevalent in both groups (xerophthalmia 89%, xerostomia 84%). In the systemic group, musculoskeletal involvement was most common, particularly arthritis (38%), followed by cutaneous manifestations (26%), cytopenias (19%), pulmonary involvement (16%), and renal or central nervous involvement (5%). ESSDAI scores were significantly higher in patients with systemic involvement (13.9 ± 21.7 vs. 4.0 ± 7.9; Conclusion: Adequate stratification of pSjD according to presence or absence of systemic manifestations is mandatory. Our results encourage a close follow-up of systemic pSjD phenotype, particularly for early diagnosis of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.